AZ/Daiichi’s Enhertu gains second ‘breakthrough’ tag in space of a week

The FDA has said AstraZeneca and Daiichi Sankyo’s Enhertu could be a breakthrough in a potential new lung cancer niche, the second time in the space of a week that the drug has received the designation.